PL234887B1 - Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej - Google Patents

Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej Download PDF

Info

Publication number
PL234887B1
PL234887B1 PL401934A PL40193412A PL234887B1 PL 234887 B1 PL234887 B1 PL 234887B1 PL 401934 A PL401934 A PL 401934A PL 40193412 A PL40193412 A PL 40193412A PL 234887 B1 PL234887 B1 PL 234887B1
Authority
PL
Poland
Prior art keywords
ppi
mal
cells
iii
dendrimer
Prior art date
Application number
PL401934A
Other languages
English (en)
Polish (pl)
Other versions
PL401934A1 (pl
Inventor
Ida FRANIAK-PIETRYGA
Ida Franiak-Pietryga
Maria BRYSZEWSKA
Maria Bryszewska
Dietmar Appelhans
Barbara KLAJNERT
Barbara Klajnert
Original Assignee
Univ Lodzki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Lodzki filed Critical Univ Lodzki
Priority to PL401934A priority Critical patent/PL234887B1/pl
Priority to KR1020157018092A priority patent/KR20150099539A/ko
Priority to PCT/PL2013/000154 priority patent/WO2014088434A1/en
Priority to CA2896673A priority patent/CA2896673A1/en
Priority to JP2015546418A priority patent/JP2016501260A/ja
Priority to US14/650,458 priority patent/US20150320692A1/en
Priority to EP13821003.4A priority patent/EP2928478A1/en
Priority to AU2013356792A priority patent/AU2013356792A1/en
Publication of PL401934A1 publication Critical patent/PL401934A1/pl
Priority to IL239143A priority patent/IL239143A0/en
Publication of PL234887B1 publication Critical patent/PL234887B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL401934A 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej PL234887B1 (pl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL401934A PL234887B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
KR1020157018092A KR20150099539A (ko) 2012-12-06 2013-12-03 말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-DS-Mal-III의 적용
PCT/PL2013/000154 WO2014088434A1 (en) 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
CA2896673A CA2896673A1 (en) 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
JP2015546418A JP2016501260A (ja) 2012-12-06 2013-12-03 マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−DS−Mal−IIIの使用
US14/650,458 US20150320692A1 (en) 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
EP13821003.4A EP2928478A1 (en) 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
AU2013356792A AU2013356792A1 (en) 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-DS-Mal-III
IL239143A IL239143A0 (en) 2012-12-06 2015-06-02 Application of fourth-generation polypropyleneamine dendrimer ppi–g4–ds–mal–iii coated with maltodextrin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL401934A PL234887B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Publications (2)

Publication Number Publication Date
PL401934A1 PL401934A1 (pl) 2014-06-09
PL234887B1 true PL234887B1 (pl) 2020-04-30

Family

ID=49955471

Family Applications (1)

Application Number Title Priority Date Filing Date
PL401934A PL234887B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Country Status (9)

Country Link
US (1) US20150320692A1 (cg-RX-API-DMAC10.html)
EP (1) EP2928478A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016501260A (cg-RX-API-DMAC10.html)
KR (1) KR20150099539A (cg-RX-API-DMAC10.html)
AU (1) AU2013356792A1 (cg-RX-API-DMAC10.html)
CA (1) CA2896673A1 (cg-RX-API-DMAC10.html)
IL (1) IL239143A0 (cg-RX-API-DMAC10.html)
PL (1) PL234887B1 (cg-RX-API-DMAC10.html)
WO (1) WO2014088434A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL234888B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208580A1 (en) * 2005-09-19 2009-08-20 Regents Of The University Of Michigan Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
US20110177602A1 (en) * 2007-06-27 2011-07-21 Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG Composite Structure
PL234888B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Also Published As

Publication number Publication date
JP2016501260A (ja) 2016-01-18
EP2928478A1 (en) 2015-10-14
US20150320692A1 (en) 2015-11-12
KR20150099539A (ko) 2015-08-31
IL239143A0 (en) 2015-07-30
AU2013356792A1 (en) 2015-07-23
CA2896673A1 (en) 2014-06-12
PL401934A1 (pl) 2014-06-09
WO2014088434A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
Ashrafizadeh et al. (Nano) platforms in breast cancer therapy: drug/gene delivery, advanced nanocarriers and immunotherapy
Zhang et al. Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models
Sun et al. Light-activated gold–selenium core–shell nanocomposites with NIR-II photoacoustic imaging performances for heart-targeted repair
Cosco et al. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer
Zhao et al. Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption
Tian et al. Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery
Cheng et al. Carrier‐Free Nanoassembly of Curcumin–Erlotinib Conjugate for Cancer Targeted Therapy
Gorzkiewicz et al. Dendrimers as nanocarriers for nucleoside analogues
Zhang et al. Hypoxia-triggered tumor specific glutamine inhibition for reversing cisplatin resistance of chemotherapy
US10925852B2 (en) Talc-bound compositions and uses thereof
CN113631193A (zh) 用于治疗癌症的金属螯合剂组合疗法
WO2019073296A1 (en) LIPOSOMAL FORMULATIONS OF BISANTRENE OR DERIVATIVES OR THE LIKE THEREOF
WO2020031136A1 (en) Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
PL234888B1 (pl) Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
EP4247407A1 (en) Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer
KR20190075389A (ko) 항암제가 담지된 나노구조체를 유효성분으로 포함하는 간암 치료용 약학조성물
US20150320692A1 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
WO2017163124A2 (en) Medical use of poly(propylene imine) glycodendrimers
PL238795B1 (pl) Ekstrakt z grzyba poliporoidalnego, kompozycja zawierająca taki ekstrakt oraz jego zastosowanie
JP6258202B2 (ja) がん療法における標的リポソーム
Dohadwala et al. Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm
Kumar et al. Targeted delivery of paromomycin to leishmania infected macrophage by hemoglobin tagged nanocarrier
Huang et al. Preparation and biocompatibility evaluation of PEG-PLL/RGD-PEG-DSPE/Phospholipid/CaP nanoparticles
US20180153927A1 (en) Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III
JPH08509961A (ja) 低密度リポタンパク質および細胞毒性物質の使用